Trials / Recruiting
RecruitingNCT07072169
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in adult patients with relapsed or refractory CD19-positive B-NHL, This study included dose escalation and dose expansion parts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABO2203 Injection | SC or IV |
Timeline
- Start date
- 2025-05-26
- Primary completion
- 2026-06-01
- Completion
- 2027-05-01
- First posted
- 2025-07-18
- Last updated
- 2025-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07072169. Inclusion in this directory is not an endorsement.